Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 36Neoplasms, Plasma Cell 12Prostatic Neoplasms 4Neoplasms 3Lymphoma, Mantle-Cell 3Immunoglobulin Light-chain Amyloidosis 3Central Nervous System Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Amyloidosis 2Adenocarcinoma of Lung 2Renal Insufficiency, Chronic 1Renal Insufficiency 1Polyneuropathies 1Paraproteinemias 1Neurotoxicity Syndromes 1Motor Activity 1

Interventions

Dexamethasone 2Azacitidine 2sacubitril and valsartan sodium hydrate drug combination 1regorafenib 1pevonedistat 1melflufen 1glucarpidase 1gamma-Glutamyl Hydrolase 1copanlisib 1carfilzomib 1Thalidomide 1Methotrexate 1Leucovorin 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Cyclophosphamide 1Bortezomib 1Bendamustine Hydrochloride 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Renal Insufficiency × Thalidomide × Clear all
NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡